Form 4: Twist Bioscience Exec Trades Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Emily M. Leproust, CEO of Twist Bioscience Corp, executed a transaction under a Rule 10b5-1 trading plan, selling 18,880 shares of common stock.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a transaction on June 25, 2026.
- The transaction involved the sale of 18,880 shares of common stock.
- This sale was conducted under a Rule 10b5-1 trading plan, adopted on May 27, 2025, which is designed to satisfy affirmative defense conditions for Rule 10b5-1(c).
- Following this transaction, Leproust beneficially owns 824,039 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the transaction was conducted under a pre-established Rule 10b5-1 plan, indicating a planned divestiture rather than a reaction to new information.
Negatives
- The CEO sold a significant number of shares (18,880) of common stock.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances. The significance of this sale depends on the executive's overall holdings and the company's current valuation and performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Trading Plan | Emily M. Leproust adopted a Rule 10b5-1 trading plan on May 27, 2025, for the sale of equity securities. | 05/27/2025 | This plan allows for the execution of trades at predetermined times and prices, providing a defense against insider trading allegations and demonstrating adherence to corporate governance best practices for insider transactions. |
Stakeholder Impact
- Shareholders: The sale by the CEO may be perceived negatively by some shareholders, although the use of a Rule 10b5-1 plan mitigates concerns about insider trading. The impact is likely limited given the planned nature of the transaction and the remaining substantial beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 05/27/2025 | Date Rule 10b5-1 trading plan was adopted by Emily M. Leproust. |
| 06/25/2026 | Transaction date for the sale of common stock. |
| 06/26/2026 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Twist Bioscience, CEO, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.